Epidemiology and management of liver metastases from colorectal cancer

S Manfredi, C Lepage, C Hatem, O Coatmeur… - Annals of …, 2006 - journals.lww.com
S Manfredi, C Lepage, C Hatem, O Coatmeur, J Faivre, AM Bouvier
Annals of surgery, 2006journals.lww.com
Objective/Background: Little is known about the epidemiology and the management of liver
metastases from colorectal cancer at a population level. The aim of this population-based
study was to report on the incidence, treatment, and prognosis of synchronous and
metachronous liver metastases. Methods: Data were obtained from the population-based
cancer registry of Burgundy (France). Results: The proportion of patients with synchronous
liver metastases was 14.5%. Age-standardized incidence rates were 7.6 per 100,000 in …
Objective/Background: Little is known about the epidemiology and the management of liver metastases from colorectal cancer at a population level. The aim of this population-based study was to report on the incidence, treatment, and prognosis of synchronous and metachronous liver metastases.
Methods: Data were obtained from the population-based cancer registry of Burgundy (France).
Results: The proportion of patients with synchronous liver metastases was 14.5%. Age-standardized incidence rates were 7.6 per 100,000 in males, 3.7 per 100,000 in females. The 5-year cumulative metachronous liver metastasis rate was 14.5%. It was 3.7% for TNM stage I tumors, 13.3% for stage II, and 30.4% for stage III (P< 0.001). The risk of liver metastasis was also associated to gross features. Resection for cure was performed in 6.3% of synchronous liver metastases and 16.9% of metachronous liver metastases. Age, presence of another site of recurrence, and period of diagnosis were independent factors associated with the performance of a resection for cure. The 1-and 5-year survival rates were 34.8% and 3.3% for synchronous liver metastases. Their corresponding rates were, respectively, 37.6% and 6.1% for metachronous liver metastases.
Conclusion: Liver metastases from colorectal cancer remain a substantial problem. More effective treatments and mass screening represent promising approaches to decrease this problem.
Lippincott Williams & Wilkins